ERBB2 and breast cancer: In Table 1, 30.6% (167/545) of breast cancer patients showed positive serum HER‐2 ECD expression (≥15 ng/mL), while 5% (6/118) of benign and 4% (3/75) of healthy controls were positive, respectively.